首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Necessity and requirements of bridging studies and their present status in Japan.
【24h】

Necessity and requirements of bridging studies and their present status in Japan.

机译:衔接研究的必要性和要求及其在日本的现状。

获取原文
获取原文并翻译 | 示例
           

摘要

The mainstays of the harmonized final document about ethnic factors in the acceptability of foreign clinical data include a complete clinical data package and a bridging study (for efficacy and/or for safety). A clinical data package that meets all of the regional regulatory requirements is defined as a complete clinical data package for submission and potential approval, irrespective of its geographic origin. The acceptability of the foreign clinical data component of the complete data package depends upon whether it can be extrapolated or employed as a bridge to the population of the new region. Ethnic factors can be defined as the intrinsic characteristics of recipients of a medicine, and extrinsic characteristics associated with the environment and culture in which the subjects reside. Based on retrospective studies, inter-ethnic differences in ADME seem to be not greater than intra-ethnic variations for most medicines, and extrinsic factors appear to be more important than intrinsic factors for the assessment of efficacy and safety of the drug across ethnicity. Medical practice may represent one of the biggest differences and may perhaps prove to be very difficult to provide a harmonization for these extrinsic factors. The bridging study concept has primarily been brought up to overcome the difficulties inherent to extrinsic factors caused by different ethnicity. In Japan, the clinical trials advice division of the organization for pharmaceutical safety and research (OPSR) has been dealing with consultations about bridging studies since February 1998. The contents of consultations can be classified into 5 types. The most common type involves the desire by industries to bridge or extrapolate the results of foreign, phase III, clinical studies by conducting the dose-response studies domestically in the form of bridging studies. Until we have more information and have collected experiences in the variations caused by the regional differences as a result of extrinsic as well as intrinsic ethnic factors, we hope and believe that this document will serve to help provide great advancements in the acceptance of foreign clinical data.
机译:关于种族因素在外国临床数据的可接受性方面的统一最终文件的主要内容包括完整的临床数据包和桥接研究(出于疗效和/或安全性考虑)。符合所有区域法规要求的临床数据包被定义为完整的临床数据包,无论其地理来源如何,都可以提交和潜在批准。完整数据包中外来临床数据部分的可接受性取决于是否可以外推或将其用作通向新地区人口的桥梁。种族因素可以定义为药物接受者的内在特征,以及与受试者所居住的环境和文化相关的外在特征。根据回顾性研究,在大多数药物中,ADME的种族间差异似乎不大于种族内差异,并且外在因素似乎比内在因素对评估跨种族药物的疗效和安全性更为重要。医学实践可能是最大的差异之一,也许很难证明这些外在因素的统一。衔接研究的概念主要是为了克服由不同种族引起的外在因素所固有的困难。在日本,药品安全与研究组织(OPSR)的临床试验咨询部门自1998年2月以来一直在进行有关衔接研究的咨询。咨询的内容可分为5种。最常见的类型涉及行业希望通过以桥接研究的形式在国内进行剂量反应研究来桥接或外推国外III期临床研究的结果。在我们获得更多信息并收集由外在因素和内在种族因素导致的地区差异所导致的变异的经验之前,我们希望并相信,该文档将有助于在接受国外临床数据方面取得重大进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号